Cargando…
Cardiometabolic risk in psoriasis: differential effects of biologic agents
Psoriasis is associated to an increased risk of cardiovascular (CV) complications. Overall, the pathogenic mechanisms involved in premature CV complications in psoriasis appear to be complex and multifactorial, with traditional and nontraditional risk factors possibly contributing to the increased r...
Autor principal: | Kaplan, Mariana J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663453/ https://www.ncbi.nlm.nih.gov/pubmed/19337536 |
Ejemplares similares
-
Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis
por: Cai, Jiangluyi, et al.
Publicado: (2021) -
Advancements in the Treatment of Psoriasis: Role of Biologic Agents
por: Rich, Sheldon J., et al.
Publicado: (2004) -
Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
por: Puig, Lluís
Publicado: (2017) -
Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis
por: Hagino, Teppei, et al.
Publicado: (2023) -
Double trouble: psoriasis and cardiometabolic disorders
por: Nasrin, Goolam Mahyoodeen, et al.
Publicado: (2018)